ANDA User Fee Proposal From Industry Relies Heavily On Establishment Fees
This article was originally published in The Pink Sheet Daily
Executive Summary
The plan would require 80% of generic drug user fee revenue to come from finished dosage manufacturers and 20% from API manufacturers.